Serial No.: 08/123,456 Group Art Unit No.: 1201

1 - 17 (Cancelled)

18. (Previously Presented) A compound of the formula (IB):

in which:

R^a and R^b together with the pyrimidine ring carbon atoms to which they are attached form a fused 5-membered carbocyclic ring;

R² is phenyl, substituted by one to three fluorine atoms;

R3 is methyl or C(1-3)alkyl substituted by NR8R9; or

 R^3 is $\text{Het-C}_{(0-2)}$ alkyl in which Het is a 5- to 7- membered heterocyclyl ring having N and in which N is unsubstituted or substituted by $C_{(1-6)}$ alkyl;

R4 and R5 together form a 4-(4-trifluoromethylphenyl)phenyl moiety;

 R^8 and R^9 which may be the same or different are selected from the group consisting of hydrogen, or $C_{(1-6)}$ alkyl);

X is S, or

a pharmaceutically acceptable salt thereof;

excluding the compound 1-(N-(2-(diethylamino)ethyl)-N-(4-(4trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6trimethylenepyrimidin-4-one, and pharmaceutically acceptable salts thereof.

19. (Previously Presented) A compound as claimed in claim 18 which is:

1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(3,4-difluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one; Serial No.: 08/123,456 Group Art Unit No.: 1201

1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(2,3,4-trifluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;

1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)amino-carbonylmethyl)-2-(2-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;

1-(N-methyl-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;

1-(N-(2-(1-piperidino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)amino-carbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;

1-(N-(1-ethylpiperidin-4-yl)-N-(4-(4-trifluoromethylphenyl)benzyl)amino-carbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;

1-(N-(2-ethylamino-2-methylpropyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;

N-(2-tert-butylaminoethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)amino-carbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;

 $1-(N-(1-methylpiperidin-4-yl)-N-(4-(4-trifluoromethylphenyl)benzyl)-\\ aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;$

1-(N-(1-isopropylpiperidin-4-yl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one;

1-(N-(1-(2-methoxyethyl)piperidin-4-yl)-N-(4-(4-trifluoromethylphenyl)benzyl)-aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5.6-trimethylenepyrimidin-4-one;

1-(N-(2-(ethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one; or a pharmaceutically acceptable salt thereof.

20. (Cancelled)

21. (Cancelled)

-4-

Serial No.: 08/123,456 Group Art Unit No.: 1201

22. (Previously Presented) A pharmaceutical composition comprising a compound of formula (IB) as claimed in claim 18 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

23. - 26. (Cancelled)

27. (Previously Presented) A method for treating atherosclerosis which method comprises administering a therapeutically effective amount of a compound of formula (IB) as claimed in claim 18 or a pharmaceutically acceptable salt thereof, to a patient in need thereof either alone or combined with a pharmaceutically acceptable excipient.